Posted by Michael Wonder on 30 Jul 2024
FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for multiple myeloma
30 July 2024 - Today, the FDA approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen) in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT).
Efficacy was evaluated in PERSEUS, an open-label, randomised, active-controlled trial in patients with newly diagnosed multiple myeloma eligible for ASCT.
